Jazz Pharmaceuticals (JAZZ) announced the appointment of Thomas Riga as Chief Business Officer, effective January 1. Riga joined Jazz in April 2025 through the acquisition of Chimerix, where he served as chief operating and commercial officer.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley
- Buy Rating on Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path in First-Line HER2+ GEA
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint of PFS
- Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial
- Jazz reports efficacy, safety results from Phase 3 HERIZON-GEA-01 trial